Briana Contreras

Primary care dementia program adds community health workers to streamline screening, workups, and family guidance for earlier Alzheimer’s care.

A study across B-cell lymphomas shows zanubrutinib delivers higher complete and overall response rates than acalabrutinib or ibrutinib, guiding BTK inhibitor choice.

James Ellison, M.D., M.P.H., and IBX’s Rodrigo Cerdá, M.D., M.P.H., back Jefferson Health primary care screening to catch dementia care needs early and coordinate support.

Phase 4 acute pain study shows Journavx helps more than 90% of plastic surgery patients achieve opioid-free recovery with strong ratings and mild side effects.

Vakharia was in the inaugural class of our Emerging Leaders in Healthcare recognition program in 2017. We circled back to find out what he is up to.

As World Obesity Day spotlights rising obesity rates, GLP-1s reshape treatment and coverage debates, with persistence, affordability and long-term value driving payer decisions.

Zahra Mahmoudjafari explains how cell and gene therapy programs succeed with strong infrastructure, pharmacy leadership, payer alignment, and workflows protecting safety and finances.

AI in managed care cuts documentation and burnout, but ROI, governance and transparency define success—learn what leaders must track and safeguard.

GLP‑1 drugs transform obesity and diabetes care, but soaring employer costs spark new coverage rules, safety concerns, and major pipeline updates.

Zahra Mahmoudjafari shares how The University of Kansas Cancer Center builds sustainable cell and gene therapy programs amid new CMS access rules.

Cardinal Health 2026 Biosimilars Report shows biosimilars’ savings surge, but predictable reimbursement drives physician adoption amid FDA streamlining.

Early pharmacy leadership helps health systems build safe, sustainable cell and gene therapy programs, aligning contracts, workflows, regulations and payer realities.

Health systems learn why cell and gene therapy success depends on workflows, staffing, and finances—not just science—and how to build them.

In this Q&A, Jessica Vazzaz explained what evidence supports sonic sleep aids, who benefits and what payers should demand before covering sleep-disorder apps.

FDA reviews tirabrutinib for relapsed/refractory primary CNS lymphoma under accelerated approval, with promising phase 2 response rates and a Dec. 2026 decision.

Jessica Vazzaz, a doctoral researcher and tutor in psychology at the University of Sussex, shared that health plans should require large, well-designed randomized trials before covering sonic sleep aids. She added that benefits are likely fair and could vary by individual, making it critical to understand who these tools actually help and under what conditions.

Real-world China study uses Markov modeling to show surgery may beat radiotherapy on cost per QALY for ESCC, despite higher upfront costs.

GLP-1 drugs boost health but challenge plastic surgery as rapid weight loss triggers facial sag and skin changes, prompting new options and lifestyle guidance.

Clinicians weigh sonic sleep tools: who benefits, how to use phone-based audio safely and why CBT-I stays first-line for insomnia.

GLP-1 weight-loss drugs can trigger facial fat loss, deepening wrinkles and sagging; experts warn appearance concerns may reduce adherence and affect health outcomes.

COVID-19 care disruptions cut U.S. one-year cancer survival, adding 17,390 deaths; see which cancers and groups were hit hardest.

Study finds transfusion access drives hospice choices in advanced blood cancers, urging new models that offer palliative transfusions with comfort care.

Recent research compares sleep aids in apps—sonic sleep sounds, white noise and pink noise—and warns weak evidence may waste money and delay proven insomnia care.

Patients using GLP-1 medications may notice facial changes due to fat loss. Vasyukevich stresses education and options for maintaining a youthful appearance.

Ten Medicaid tech companies pledge over $600 million in support to help states meet new community engagement requirements and modernize eligibility systems.